Sulfate ion Not Yet Recruiting Phase 2 Trials for Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma / Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Aggressive Non-Hodgkin Lymphoma / Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements / Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma / Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma / Indolent Non-Hodgkin's Lymphomas / Transformed Non-Hodgkin Lymphoma / High Grade B-Cell Lymphoma, Not Otherwise Specified / Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma / Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03749018Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma